ArticleFrontiers in oncology2026
Dual-region deep learning model integrating prostate and peri-prostatic adipose tissue MRI features for bone metastasis prediction in prostate cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale and objectives: Bone metastasis (BM) is pivotal in prostate cancer (PCa) management. This study developed a multimodal model integrating MRI-derived deep features from the prostate gland (PG) and periprostatic adipose tissue (PPAT) with clinical variables for BM risk assessment. Methods: Retrospectively, 464 patients were recruited and randomly divided into training and internal test cohorts at a ratio of 7:3. Deep features were extracted from PG and PPAT regions on T2-weighted MRI using a pretrained ResNet-50 as a fixed feature extractor. Clinical, PG, and PPAT component models were developed using patient-level cross-validation. Their out-of-fold probabilities were integrated by a logistic-regression meta-learner to construct the Deep feature-based PG-PPAT-Clinical (DPPC) model. Model performance was evaluated using ROC-AUC, average precision, calibration analysis, decision-curve analysis, and SHAP analysis. Results: The DPPC model achieved ROC-AUCs of 0.922 (95% CI, 0.887-0.954) in the training cohort and 0.928 (95% CI, 0.864-0.978) in the internal test cohort. Its ROC-AUC was significantly higher than that of the Clinical model in the training cohort and the PPAT model in the internal test cohort, whereas the remaining pairwise differences were not statistically significant. At a probability threshold of 0.5, the internal-test sensitivity and specificity were 65.1% and 95.9%, respectively. The observed BM rates were 87.5% in the high-risk group and 13.9% in the low-risk group. Conclusion: By synergizing deep learning signatures from PG and PPAT with clinical factors, the DPPC model demonstrates promising performance for BM risk stratification, and external validation and further calibration assessment are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.